In Q1 and Q2 of calendar 2025, Medicenna anticipates achieving several milestones in the MDNA11 program. These include completing monotherapy expansion and combination dose-escalation enrollment, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback